C. Tamminga

Publications225
h-index56
Citations12,489
Highly Influential Citations419
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • D. Weinberger
  • 1,116 Publications, 116,130 Citations
  • C. Tamminga
  • 439 Publications, 10,312 Citations
  • E. Nestler
  • 805 Publications, 103,381 Citations
  • G. Pearlson
  • 740 Publications, 45,986 Citations
  • Publications
  • Influence
Molecular Adaptations Underlying Susceptibility and Resistance to Social Defeat in Brain Reward Regions
While stressful life events are an important cause of psychopathology, most individuals exposed to adversity maintain normal psychological functioning. The molecular mechanisms underlying such… Expand
  • 1,444
  • 127
  • PDF
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects.
BACKGROUND Suicide is a major public health concern. Although authors of many studies have examined the neurobiological aspects of suicide, the molecular mechanisms associated with suicidal behavior… Expand
  • 689
  • 21
  • PDF
Effects of Ketamine in Normal and Schizophrenic Volunteers
This study evaluates the effects of ketamine on healthy and schizophrenic volunteers (SVs) in an effort to define the detailed behavioral effects of the drug in a psychosis model. We compared the… Expand
  • 566
  • 17
  • PDF
Ketamine activates psychosis and alters limbic blood flow in schizophrenia
The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking… Expand
  • 418
  • 14
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
OBJECTIVE This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the… Expand
  • 290
  • 13
The initial field trials of DSM-5: new blooms and old thorns.
Three articles in this issue detail the process and results of reliability tests for proposed DSM-5 diagnoses and cross-diagnosis symptom domains. The editorial highlights the good reliability of… Expand
  • 180
  • 13
  • PDF
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.
OBJECTIVE Familial neuropsychological deficits are well established in schizophrenia but remain less well characterized in other psychotic disorders. This study from the Bipolar-Schizophrenia Network… Expand
  • 237
  • 12
Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
OBJECTIVE The functional pathways through which antipsychotic drugs act in the brain to decrease psychosis remain unknown, despite our knowledge that their site of initial action is through blockade… Expand
  • 211
  • 10
Phenotype of schizophrenia: a review and formulation
The discovery of the pathophysiology(ies) for schizophrenia is necessary to direct rational treatment directions for this brain disorder. Firm knowledge about this illness is limited to areas of… Expand
  • 226
  • 10
  • PDF
Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia.
OBJECTIVE Multiple quantifiable biologic abnormalities have been localized to the hippocampus in schizophrenia. Alterations in glutamate-mediated transmission at N-methyl-D-aspartic acid… Expand
  • 365
  • 9
  • PDF